Youakim Saliba1, Victor Jebara2, Joelle Hajal1, Richard Maroun3, Stéphanie Chacar1,3, Viviane Smayra2, Joel Abramowitz4, Lutz Birnbaumer4,5, Nassim Farès1. 1. 1 Laboratoire de Recherche en Physiologie et Physiopathologie, Pôle Technologie Santé, Faculté de Médecine, Université Saint Joseph, Beirut, Lebanon. 2. 2 Faculté de Médecine, Université Saint Joseph, Beirut, Lebanon. 3. 3 Unité de Recherche Technologie et Valorisation Alimentaire, Centre d'Analyses et de Recherche, Faculté des Sciences, Université Saint-Joseph, Beirut, Lebanon. 4. 4 Neurobiology Laboratory, National Institute of Environmental Health Sciences, Durham, North Carolina. 5. 5 Institute of Biomedical Research (BIOMED), School of Medicine, Catholic University of Argentina, Buenos Aires, Argentina.
Abstract
AIMS: Cardiac fibroblasts (CFs) are emerging as major contributors to myocardial fibrosis (MF), a final common pathway of many etiologies of heart disease. Here, we studied the functional relevance of transient receptor potential canonical 3 (TRPC3) channels and nuclear factor of activated T cells c3 (NFATc3) signaling in rodent and human ventricular CFs, and whether their modulation would limit MF. RESULTS: A positive feedback loop between TRPC3 and NFATc3 drove a rat ventricular CF fibrotic phenotype. In these cells, polyphenols (extract of grape pomace polyphenol [P.E.]) decreased basal and angiotensin II-mediated Ca2+ entries through a direct modulation of TRPC3 channels and subsequently NFATc3 signaling, abrogating myofibroblast differentiation, fibrosis and inflammation, as well as an oxidative stress-associated phenotype. N(ω)-nitro-l-arginine methyl ester (l-NAME) hypertensive rats developed coronary perivascular, sub-epicardial, and interstitial fibrosis with induction of embryonic epicardial progenitor transcription factors in activated CFs. P.E. treatment reduced ventricular CF activation by modulating the TRPC3-NFATc3 pathway, and it ameliorated echocardiographic parameters, cardiac stress markers, and MF in l-NAME hypertensive rats independently of blood pressure regulation. Further, genetic deletion (TRPC3-/-) and pharmacological channel blockade with N-[4-[3,5-Bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-methyl-benzenesulfonamide (Pyr10) blunted ventricular CF activation and MF in l-NAME hypertensive mice. Finally, TRPC3 was present in human ventricular CFs and upregulated in MF, whereas pharmacological modulation of TRPC3-NFATc3 decreased proliferation and collagen secretion. Innovation and Conclusion: We demonstrate that TRPC3-NFATc3 signaling is modulated by P.E. and critically regulates ventricular CF phenotype and MF. These findings strongly argue for P.E., through TRPC3 targeting, as potential and interesting therapeutics for MF management.
AIMS: Cardiac fibroblasts (CFs) are emerging as major contributors to myocardial fibrosis (MF), a final common pathway of many etiologies of heart disease. Here, we studied the functional relevance of transient receptor potential canonical 3 (TRPC3) channels and nuclear factor of activated T cells c3 (NFATc3) signaling in rodent and human ventricular CFs, and whether their modulation would limit MF. RESULTS: A positive feedback loop between TRPC3 and NFATc3 drove a ratventricular CF fibrotic phenotype. In these cells, polyphenols (extract of grape pomace polyphenol [P.E.]) decreased basal and angiotensin II-mediated Ca2+ entries through a direct modulation of TRPC3 channels and subsequently NFATc3 signaling, abrogating myofibroblast differentiation, fibrosis and inflammation, as well as an oxidative stress-associated phenotype. N(ω)-nitro-l-arginine methyl ester (l-NAME) hypertensiverats developed coronary perivascular, sub-epicardial, and interstitial fibrosis with induction of embryonic epicardial progenitor transcription factors in activated CFs. P.E. treatment reduced ventricular CF activation by modulating the TRPC3-NFATc3 pathway, and it ameliorated echocardiographic parameters, cardiac stress markers, and MF in l-NAMEhypertensiverats independently of blood pressure regulation. Further, genetic deletion (TRPC3-/-) and pharmacological channel blockade with N-[4-[3,5-Bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-methyl-benzenesulfonamide (Pyr10) blunted ventricular CF activation and MF in l-NAMEhypertensivemice. Finally, TRPC3 was present in human ventricular CFs and upregulated in MF, whereas pharmacological modulation of TRPC3-NFATc3 decreased proliferation and collagen secretion. Innovation and Conclusion: We demonstrate that TRPC3-NFATc3 signaling is modulated by P.E. and critically regulates ventricular CF phenotype and MF. These findings strongly argue for P.E., through TRPC3 targeting, as potential and interesting therapeutics for MF management.
Authors: Sandra B Haudek; Ying Xia; Peter Huebener; John M Lee; Signe Carlson; Jeff R Crawford; Darrell Pilling; Richard H Gomer; JoAnn Trial; Nikolaos G Frangogiannis; Mark L Entman Journal: Proc Natl Acad Sci U S A Date: 2006-11-17 Impact factor: 11.205
Authors: Alexander Dietrich; Michael Mederos Y Schnitzler; Maik Gollasch; Volkmar Gross; Ursula Storch; Galyna Dubrovska; Michael Obst; Eda Yildirim; Birgit Salanova; Hermann Kalwa; Kirill Essin; Olaf Pinkenburg; Friedrich C Luft; Thomas Gudermann; Lutz Birnbaumer Journal: Mol Cell Biol Date: 2005-08 Impact factor: 4.272
Authors: Erik R Olson; Jennifer E Naugle; Xiaojin Zhang; Joshua A Bomser; J Gary Meszaros Journal: Am J Physiol Heart Circ Physiol Date: 2004-10-21 Impact factor: 4.733
Authors: Koichiro Kuwahara; Yanggan Wang; John McAnally; James A Richardson; Rhonda Bassel-Duby; Joseph A Hill; Eric N Olson Journal: J Clin Invest Date: 2006-11-09 Impact factor: 14.808
Authors: Juan E Camacho Londoño; André Marx; Axel E Kraft; Alexander Schürger; Christin Richter; Alexander Dietrich; Peter Lipp; Lutz Birnbaumer; Marc Freichel Journal: Cells Date: 2020-01-29 Impact factor: 6.600
Authors: Débora Falcón; Isabel Galeano-Otero; Marta Martín-Bórnez; María Fernández-Velasco; Isabel Gallardo-Castillo; Juan A Rosado; Antonio Ordóñez; Tarik Smani Journal: Cells Date: 2020-01-10 Impact factor: 6.600